TFF Pharmaceuticals announces its new partnership with Emory University and the Biomedical Advanced Research and Development Authority, BARDA. Under the partnership, TFF Pharmaceuticals will test the feasibility of converting Emory’s mRNA-based Cas13a antiviral against influenza A and B and SARS-CoV-2 into a dry powder formulation for more precise inhalational delivery, improved stability and widespread distribution without the need for cold-chain storage.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TFFP:
- TFF Pharmaceuticals announces preclinical data from influenza vaccine candidates
- TFF Pharmaceuticals Announces Positive Preclinical Data from Bivalent Universal Influenza Vaccine Candidates Manufactured by TFF Following Intranasal Immunization
- TFFP Upcoming Earnings Report: What to Expect?
- TFF Pharmaceuticals Shares Update on Recent Developments
- TFF Pharmaceuticals provides continued positive outfomes from TFF TAC
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue